An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis

Authors

Ilya Gertsman, University of California - San Diego
Joanne Wuu, University of Miami
Melissa McAlonis-Downes, University of California - San Diego
Majid Ghassemian, University of California - San Diego
Karen Ling, Ionis Pharmaceuticals, Carlsbad
Frank Rigo, Ionis Pharmaceuticals, Carlsbad
Frank Bennett, Ionis Pharmaceuticals, Carlsbad
Michael Benatar, University of Miami
Timothy M. Miller, Washington University School of Medicine in St. Louis
Sandrine Da Cruz, University of California - San Diego

Journal

JCI Insight

Publication Date

5-16-2019

Volume

4

Issue

10

First Page

e122768

Document Type

Open Access Publication

DOI

10.1172/jci.insight.122768

Rights and Permissions

Gertsman I, Wuu J, McAlonis-Downes M, Ghassemian M, Ling K, Rigo F, Bennett F, Benatar M, Miller TM, Da Cruz S. An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight. 2019 May 16;4(10):e122768. doi: 10.1172/jci.insight.122768. © 2019 American Society for Clinical Investigation

Recommended Citation

Gertsman, Ilya; Wuu, Joanne; McAlonis-Downes, Melissa; Ghassemian, Majid; Ling, Karen; Rigo, Frank; Bennett, Frank; Benatar, Michael; Miller, Timothy M.; and Da Cruz, Sandrine, "An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis." JCI Insight. 4, 10. e122768 (2019).
https://digitalcommons.wustl.edu/open_access_pubs/10867